Abstract
Rationale & Objective Person-centered care (PCC), which incorporates patients’ preferences and values not only for medical care but also for their life, in decision making has been proposed for promoting advance care planning (ACP) among patients with kidney failure.
However, how variations in PCC affect ACP participation remain unclear. Therefore, we examined variations in PCC across facilities and examined the association between PCC and ACP participation.
Study Design Multicenter cross-sectional study.
Setting & Participants Japanese adults receiving outpatient hemodialysis at six dialysis centers.
Exposures PCC was measured using the 13-item Japanese version of the Primary Care Assessment Tool-short form.
Outcome ACP participation as defined by discussion with the attending physician or written documentation or notes regarding treatment preferences.
Analytical Approach A general linear model was used to examine the correlates of the quality of PCC. Modified Poisson regression models were used to examine the associations of ACP participation.
Results A total of 453 individuals were analyzed; 26.3% participated in ACP. Compared to respondents with no usual source of care (USC), higher PCC was associated with greater ACP participation in a dose-response manner (vs. no USC, adjusted prevalence ratios for the first to fourth quartiles: 1.36, 2.31, 2.64, and 3.10, respectively). Among the PCC sub-domains, first contact, longitudinality, comprehensiveness (services provided), and community orientation were particularly associated with ACP participation. There was a maximum of 12.0 points of facility variation in the quality of PCC.
Limitations Possible reverse causation and unmeasured confounders.
Conclusions High PCC quality was associated with ACP participation. The substantial disparity in PCC between facilities provides an opportunity to revisit the quality improvement in PCC.
Competing Interest Statement
NK received grants from the Japan Society for the Promotion of Science, consulting fees from GlaxoSmithKline K.K., and payments for speaking and educational events from Taisho Pharmaceutical Co. Ltd. and Eisai Co. Ltd. RI received payments for speaking from Astellas Pharma, Inc., Novartis Pharma K.K., and Otsuka Pharmaceuticals. TT received payment for speaking and educational events from Otsuka Pharmaceuticals. MM received payments for speaking and educational events from Astellas Pharma Inc. and Baxter Co., Ltd. TS has received payment for speaking and educational events from Astellas Pharma Inc, AstraZeneca K.K, Baxter Co., Ltd., Bayer Yakuhin., Ltd., Bristol-Myers Squibb Co., CureApp, Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K, Kaneka Medix Corp, Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd, Mochida Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd, Novartis Pharma K.K., Novo Nordisk Pharma., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical, Terumo Corp, and Torii Pharmaceutical Co., Ltd.
Funding Statement
This study was supported by JSPS KAKENHI (grant numbers: JP19KT0021).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at Fukushima Medical University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
